Success at last: A molecular factor that informs treatment

Current Oncology Reports

Volumn 15, Issue 1, 2013, Pages 47-55

  Lassman, Andrew B ^a  

^a Department of Medicine   (United States)

Author keywords

1p 19q Deletion; Mature; Oligodendroglioma; Overall survival; PCV; Phase III; Survival; Temozolomide, progression free survival

Indexed keywords

ISOCITRATE DEHYDROGENASE; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NITROSOUREA; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADJUVANT THERAPY; ARTICLE; BRAIN SURGERY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME ARM; CHROMOSOME DELETION; DRUG TOLERABILITY; FOLLOW UP; GENE; HUMAN; IDH GENE; MGMT GENE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN METHYLATION; RADIOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CLINICAL TRIALS, PHASE III AS TOPIC; GENETIC MARKERS; HUMANS; ISOCITRATE DEHYDROGENASE; OLIGODENDROGLIOMA; PROGNOSIS; SEQUENCE DELETION; TUMOR MARKERS, BIOLOGICAL;

EID: 84872402678     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-012-0281-5     Document Type: Article

References (72)

1. Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res. 2006;12:7232-41.
2. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-19.
3. CBTRUS. Central Brain Tumor Registry of the United States (CBTRUS) statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2008 (March 23, 2012 revision). 2012. http://www.cbtrus.org. Accessed 22 Oct 2012.
4. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
5. Hofer S, Lassman AB. Molecular markers in gliomas: impact for the clinician. Target Oncol. 2010;5:201-10.
6. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27:4150-4.
7. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765-73.
8. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118:469-74.
9. Louis DN, Ohgaki H, Wiestler OD, Cavanee WK. WHO Classification of tumours of the central nervous system. 4th ed. Lyon: International Agency for Research on Cancer; 2007.
10. Giannini C, Burger PC, Berkey BA, et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol. 2008;18:360-9.
11. Giannini C, Scheithauer BW, Weaver AL, et al. Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol. 2001;60:248-62.
12. McDonald JM, See SJ, Tremont IW, et al. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer. 2005;104:1468-77.
13. Coons SW, Johnson PC, Scheithauer BW, et al. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer. 1997;79:1381-93.
14. Kros JM, Gorlia T, Kouwenhoven MC, et al. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol. 2007;66:545-51.
15. Burger PC. What is an oligodendroglioma? Brain Pathol. 2002;12:257-9.
16. Walker MD, Alexander Jr E, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49:333-43.
17. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980;303:1323-9.
18. DeAngelis LM, Burger PC, Green SB, Cairncross JG. Malignant glioma: who benefits from adjuvant chemotherapy? Ann Neurol. 1998;44:691-5.
19. Neighbors LB, Ammirati M, Bierman PJ, et al. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: central nervous system cancers (Version 2.2012). 2012. http://www.nccn.org. Accessed 22 Jul 2012.
20. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96.
21. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459-66.
22. Mason W, Louis DN, Cairncross JG. Chemosensitive gliomas in adults: which ones and why? J Clin Oncol. 1997;15:3423-6.
23. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol. 1988;23:360-4.
24. Levin VA, Edwards MS, Wright DC, et al. Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep. 1980;64:237-44.
25. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994;12:2013-21.
26. Reifenberger J, Reifenberger G, Liu L, et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol. 1994;145:1175-90.
27. Bigner SH, Matthews MR, Rasheed BK, et al. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol. 1999;155:375-86.
28. He J, Mokhtari K, Sanson M, et al. Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol. 2001;60:863-71.
29. Aldape K, Burger PC, Perry A. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med. 2007;131:242-51.
30. Kouwenhoven K, Gorlia T, Kros J, et al. EORTC 26951: prognosis of oligodendroglial tumors is an interplay of molecular, histological, and clinical characteristics. Neuro Oncol. 2007;9:546 [abstract PA-18].
31. Pinto LW, Araujo MB, Vettore AL, et al. Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis. Virchows Arch. 2008;452:481-90.
32. Kraus JA, Lamszus K, Glesmann N, et al. Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol. 2001;101:311-20.
33. Homma T, Fukushima T, Vaccarella S, et al. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol. 2006;65:846-54.
34. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006;66:9852-61.
35. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473-9.
36. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res. 2001;7:839-45.
37. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24:2707-14.
38. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24:2715-22.
39. Betensky RA, Louis DN, Cairncross JG. Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol. 2002;20:2495-9.
40. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27:5874-80.
41. Weller M, Berger H, Hartmann C, et al. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res. 2007;13:6933-7.
42. van den Bent MJ, Looijenga LH, Langenberg K, et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer. 2003;97:1276-84.
43. Cairncross G, Wang M, Chang S, et al. A randomized trial of chemotherapy plus radiotherapy (RT) versus RT alone for anaplastic oligodendroglioma (RTOG 9402): the perspective of longer follow-up. Int J Radiat Oncol Biol Phys. 2008;72:S7-8.
44. •• Cairncross G, Wang M, Shaw E et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term Results of RTOG 9402. J Clin Oncol. 2012. Final results of RTOG and EORTC trials demonstrating that in AOs, 1p/19q co-deletion predicts benefit from PCV chemotherapy added to radiotherapy, doubling survival versus radiotherapy alone. These results were elucidated only after allowing data to mature for over 10 years, and the acquisition and analysis of missing archival tumor tissue.
45. •• van den Bent MJ, Brandes AA, Taphoorn MJ et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group study 26951. J Clin Oncol. 2012. Final results of an EORTC trial conducted concurrently with the RTOG trial also demonstrating the predictive importance of 1p/19q deletion, and also achievable only after prolonged follow-up.
46. Abrey LE, Louis DN, Paleologos N, et al. Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol. 2007;9:314-8.
47. Panageas KS, Iwamoto FM, Cloughesy TF, et al. Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro Oncol. 2012;14:761-7.
48. Lassman AB, Iwamoto FM, Cloughesy TF, et al. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol. 2011;13:649-59.
49. DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology. 1989;39:789-96.
50. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10:1037-44.
51. Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8:810-8.
52. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol. 2000;18:3144-50.
53. Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. Int J Radiat Oncol Biol Phys. 2010;77:662-9.
54. Taphoorn MJ, van den Bent MJ, Mauer ME, et al. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol. 2007;25:5723-30.
55. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999;17:2762-71. Erratum in J Clin Oncol 1999;17(11):3693.
56. Diez BD, Statkevich P, Zhu Y, et al. Evaluation of the exposure equivalence of oral versus intravenous temozolomide. Cancer Chemother Pharmacol. 2010;65:727-34.
57. Motomura K, Natsume A, Wakabayashi T. Intravenous administration of temozolomide as a useful alternative over oral treatment with temozolomide capsules in patients with gliomas. J Neurooncol. 2012;106:209-11.
58. DeAngelis LM. Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. J Clin Oncol. 2009;27:5861-2 [corrected].
59. Vogelbaum MA, Berkey B, Peereboom D, et al. Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol. 2009;11:167-75.
60. Vogelbaum MA, Wang M, Peereboom DM, et al. RTOG 0131: phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas - updated survival and progression free survival analysis. Neuro Oncol. 2012;14;vi75-6 [abstract NO-56].
61. Peyre M, Cartalat-Carel S, Meyronet D, et al. Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol. 2010;12:1078-82.
62. Mason WP, Krol GS, DeAngelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology. 1996;46:203-7.
63. Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer. 2005;103:802-9.
64. Weller M. Chemotherapy for low-grade gliomas: When? How? How long? Neuro Oncol. 2010;12:1013.
65. Reiner AS, Panageas KS, Iwamoto FM, et al. Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro Oncol. 2011;13:iii43-4 [abstract NO-15].
66. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27:740-5.
67. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733-40.
68. Taillibert S, Vincent LA, Granger B, et al. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology. 2009;72:1601-6.
69. Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011;29:142-8.
70. Vredenburgh JJ, Desjardins A, Reardon DA, et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res. 2011;17:4119-24.
71. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366:985-90.
72. Simone JV. Understanding academic medical centers: Simone's maxims. Clin Cancer Res. 1999;5:2281-5.